Kidney Tumor Clinical Trial
Official title:
Sildenafil Prior to Robotic Partial Nephrectomy to Improve Postoperative Renal Function: A Randomized, Placebo-Controlled Pilot Study
This randomized pilot clinical trial studies sildenafil citrate before surgery in improving kidney function in patients with kidney cancer. Sildenafil citrate may help protect the kidney from the side effects of surgery and improve kidney function after surgery.
PRIMARY OBJECTIVES:
I. To assess accrual, retention, and participation rates for patients receiving sildenafil
(sildenafil citrate) compared to placebo in patients undergoing robotic partial nephrectomy
(RPN) for a suspected renal malignancy.
SECONDARY OBJECTIVES:
I. To evaluate individual alterations in glomerular filtration rate (GFR) at 24 hours, 48
hours and one month following RPN and compare these to the placebo group.
II. To evaluate individual alterations in proteinuria at 24 hours, 48 hours, one month and
three months following RPN and compare these to the placebo group.
III. To measure between-group differences in estimated blood loss and hemoglobin
concentration at 24 hours following RPN.
IV. To describe individual changes in blood pressure measurements as noted in the
preoperative holding area, throughout the procedure and in the post-anesthesia care unit.
V. To describe between-group variations in vasopressor support or intravenous fluid
requirements during the operative procedure.
VI. To compare overall complication rates (within 90 days postoperatively) between groups.
VII. To obtain a preliminary effect size of sildenafil on change in GFR at three months
following RPN.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive sildenafil citrate orally (PO) before the initiation of standard
robotic partial nephrectomy.
ARM II: Patients receive placebo PO before the initiation of standard robotic partial
nephrectomy.
After completion of study treatment, patients are followed up at 1 and 3 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01688414 -
Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer
|
N/A | |
Recruiting |
NCT05387863 -
Decision Aid (DA) for Renal Patients
|
N/A | |
Active, not recruiting |
NCT03819569 -
GRADE-SRM: Genomic Risk Assessment and Decisional Evaluation for Small Renal Masses
|
N/A | |
Recruiting |
NCT06056505 -
Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy
|
N/A | |
Recruiting |
NCT01967407 -
IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.
|
Phase 1/Phase 2 | |
Terminated |
NCT00960063 -
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
|
Phase 1 | |
Recruiting |
NCT05890781 -
Engineering Immune Organoids to Study Pediatric Cancer
|
N/A | |
Completed |
NCT05015179 -
Mixed Reality Technology in Laparoscopic Partial Nephrectomy
|
N/A | |
Completed |
NCT00019630 -
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT01908166 -
Ultrasound Elastography in Diagnosing Patients With Kidney or Liver Solid Focal Lesions
|
N/A | |
Recruiting |
NCT05728957 -
Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT/CT for Patients With Clinically Localized Renal Tumors
|